EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

查看全文 作　　者：Moerman RV;Arends S;Meiners PM;etal 出　　处：《Annals of the rheumatic diseases》索引2014年第2卷第73期,共0页